查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597295

内分泌检查的全球市场的评估:检验各类型，各技术，各终端用户，各地区，机会，预测(2017年～2031年)

Endocrine Testing Market Assessment, By Test Type, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 240 Pages | 商品交期: 3-5个工作天内

价格

全球内分泌检查的市场规模，被预测从2023年的130亿3,000万美元2031年达到244亿2,000万美元，2024年～2031年的预测期间年复合成长率8.17％的成长被预料。支撑市场成长，是内分泌疾病的由于罹患率的上升，预防医疗的认识的高涨，市场参与企业的功能和使患者的便利性提高了的产品的销售的增加。2023年8月，美国食品药物管理局(FDA)Mira Fertility Ovum 作为追踪尿中的滤泡促素(FSH)层级的OTC工具列表了Wand。这个wand，能生殖能力的评估，更年期的预测，排卵预测的支援转动，提供研究室正确的FSH层级。

内分泌检查，对为了特别指定内分泌系的异常和不平衡，管理生殖问题，糖尿病，甲状腺疾病等的健康状态早期发现的荷尔蒙层级的评估不可缺少。被预测由于为了强化这些的检验的点阅存取和可得性的医疗部门的投资的增加，对市场扩大带来Plus的影响。

由于为了提高对再加上一般居民的内分泌疾病的认识的高涨，及内分泌检查的可及性的各种各样的医疗机关的配合措施的增加，带来着对市场有利的成长机会。复数的医疗机关和政府机关，糖尿病和甲状腺疾病发病的风险越发用力高(贵)的族群的定期诊察。另一方面，一般居民为了从健康意识的高涨，早期发现潜在的健康问题寻求定期性的健康检查。对再加上预防医疗的转移，也促进着全世界的各种地区的内分泌检查的需求。

本报告提供全球内分泌检查市场相关调查分析，市场规模与预测，市场动态，提供着主要企业的形势等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球内分泌检查市场预测(2017年～2031年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 检验各类型
    • 各技术
    • 各终端用户
    • 各地区
    • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2023年)
  • 市场地图分析(2023年)
    • 检验各类型
    • 各技术
    • 各终端用户
    • 各地区

第5章 北美的内分泌检查市场预测(2017年～2031年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 检验各类型
    • 各技术
    • 各终端用户
    • 占有率:各国
  • 各国的市场评估
    • 美国的内分泌检查市场预测(2017年～2031年)
    • 加拿大
    • 墨西哥

第6章 欧洲的内分泌检查市场预测(2017年～2031年)

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第7章 亚太地区的内分泌检查市场预测(2017年～2031年)

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的内分泌检查市场预测(2017年～2031年)

  • 巴西
  • 阿根廷

第9章 中东·非洲的内分泌检查市场预测(2017年～2031年)

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 以色列

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

  • 临床试验
  • 法规当局的认证

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 市场领导者前五名公司的竞争矩阵
  • 前五名公司的SWOT分析
  • 主要企业前十大企业的形势
    • Abbott Laboratories
    • bioMerieux SA
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • AB Sciex Pte. Ltd.
    • DiaSorin S.p.A.
    • Quest Diagnostics Incorporated
    • Danaher Corporation

第21章 策略性推荐

第22章 本公司相关资料，免责声明

Product Code: MX12292

Global endocrine testing market is projected to witness a CAGR of 8.17% during the forecast period 2024-2031, growing from USD 13.03 billion in 2023 to USD 24.42 billion in 2031. The market's growth is supported by the rising incidences of endocrine disorders, increasing awareness about preventive healthcare, and growing product launches by market players with enhanced features and patient convenience. In August 2023, the US Food and Drug Administration (FDA) listed the Mira Fertility Ovum Wand as an over-the-counter tool for tracking follicle-stimulating hormone (FSH) levels in urine. The wand can provide lab-accurate FSH levels for assessing fertility, predicting menopause, and supporting ovulation predictions.

Endocrine testing is essential for identifying abnormalities and imbalances in the endocrine system and assessing hormone levels for management and early detection of health conditions such as reproductive issues, diabetes, and thyroid disorders. Increasing investments by the healthcare sector to bolster the accessibility and affordability of these tests are expected to influence the market's expansion positively.

Furthermore, the rising awareness among the general population about endocrine disorders and the increasing efforts by various healthcare organizations to boost the accessibility of endocrine testing are providing lucrative growth opportunities to the market. Several healthcare organizations and government institutions are increasingly focusing on regular checkups for population groups that are at a higher risk of developing diabetes and thyroid disorders. Meanwhile, the general population is seeking regular health checkups to identify potential health issues on time due to increasing health consciousness. Additionally, the shift towards preventive healthcare is also propelling the demand for endocrine testing in various regions across the globe.

Increasing Prevalence of Endocrine Disorders Boosts Market Demand

Factors such as environmental influence, lifestyle changes, and genetic predisposition contribute significantly to endocrine disorders. These disorders also occur if the body cannot respond to hormones as it is supposed to. According to a National Center for Biotechnology Information (NCBI) study, the prevalence of endocrine disorders in adults in the United States is at least 5%. The rising cases of endocrine disorders are thus bolstering the reliance on endocrine testing to detect hormonal abnormalities and identify diseases.

The increasing incidences of hypothyroidism and diabetes, coupled with the increasing awareness about such conditions, is another major factor boosting the global endocrine testing market size.

Additionally, environmental factors and evolving lifestyles are also propelling the prevalence of endocrine disorders. Rising exposure to endocrine-disrupting chemicals, poor diet, stress, and sedentary habits have also been linked with the growing incidences of endocrine diseases. Endocrine-disrupting chemicals are usually found in a wide range of products, from pesticides to plastics, and have been shown to interfere with optimal hormone functioning, resulting in conditions such as reproductive health issues and thyroid imbalance.

Development of Novel Technologies Supports Market Expansion

The development of novel products and technologies plays a vital role in expanding the global endocrine testing market. Advancements in monitoring and diagnostics allow the development of endocrine testing solutions that deliver more reliable and faster results, allowing healthcare professionals to diagnose complex hormonal issues effectively. The growing demand for efficient, accessible, and patient-friendly testing solutions is thus propelling the growth of the endocrine testing market. Healthcare companies and startups across the globe are actively working on launching newer endocrine testing devices.

In July 2023, Mylab Discovery Solutions Pvt. Ltd., a Pune-based biotech startup, launched the Mybox+ diagnostic device with a broad range of tests, including biomarker (CRP, D-Dimer), cardiac marker (Troponin), and thyroid panel (T-3, T-4, TSH). Introducing this solution and the Dry Luminescence technology shows a transformative step in diagnostics and empowers clinics and labs by allowing them to provide a wide range of tests, thus aiding them in improving patient care. This technology offers a game-changing solution for clinics and small laboratories that have previously faced limitations in performing various tests and had to rely on larger facilities, often resulting in increased costs and delayed results. Thus, developing novel technologies improves patient convenience and positively influences the expansion of the endocrine testing market.

Thyroid Stimulating Hormone (TSH) Test Accounts for Significant Market Share

The growth of the segment is supported by increasing awareness about the importance of early detection of thyroid disorders and the rising prevalence of such conditions. According to the estimates of the American Thyroid Association, approximately 20 million Americans have some type of thyroid disease. Thyroid testing focuses on checking T3, T4, and TSH levels. It is one of the most performed endocrine tests across the globe as the incidences of hyperthyroidism and hypothyroidism increase. The growing efforts by the leading market players to ensure the availability of accurate and user-friendly testing devices and home-use testing kits are also expected to bolster the segment's expansion and provide lucrative growth opportunities to the global endocrine testing market.

Additionally, the increasing integration of TSH tests in preventive healthcare practices, particularly in population groups that are at high risk or have a history of thyroid disorders, is also propelling the segment's growth. Early detection can aid healthcare providers in preventing the occurrence of serious complications, including fertility issues, metabolic problems, and cardiovascular diseases. Furthermore, a rising number of healthcare professionals are advocating regular TSH testing for patients showing non-specific symptoms such as weight changes, fatigue, and depression, further bolstering the test's demand.

North America Holds Major Market Share

The rapid expansion of the market in the region can be attributed to the expansion of the population, growth of the healthcare sector, introduction of proactive government measures and policies, increasing the burden of different diseases, and rising awareness among the patient population. The strong presence of leading market players and the easy availability of healthcare services are also positively influencing the market's expansion.

The rising cases of endocrine-related diseases such as thyroid cancer are also bolstering the market demand in North America. According to the estimates of the American Cancer Society, approximately 44,020 new cases of thyroid cancer are expected to be reported in the United States in 2024. Additionally, the presence of various organizations that monitor and screen thyroid dysfunction and are devoted to thyroid biology and prevention and treatment of various thyroid diseases also provides lucrative growth opportunities to the market.

Furthermore, the rising cases of diabetes and the increasing requirement for insulin testing are also expected to bolster the market's demand. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million individuals in the United States have diabetes.

Future Market Scenario (2024-2031F)

As per the global endocrine testing market analysis, the demand is expected to be driven by increasing emphasis on preventive healthcare, rapid advancements in diagnostic technologies, and increasing incidences of endocrine disorders. Additionally, the rising requirement for point-of-care testing and increasing integration of machine learning and artificial intelligence in diagnostics is expected to drive innovation and propel the global endocrine testing market growth. The increasing prevalence of various endocrine disorders, including thyroid disorders and diabetes, in combination with supportive reimbursement policies, is expected to drive the global endocrine testing market demand. As per the estimates by the International Diabetes Federation (IDF), approximately 783 million individuals across the globe will be living with diabetes by 2045.

Additionally, the rapid expansion of the population and increasing burden on the healthcare sector are also expected to provide lucrative growth opportunities for the market. Endocrine testing is usually deployed in cases where doctors suspect that the patient might have an endocrine disorder or receive abnormal results for other function studies. The blood tests aid in confirming or eliminating suspicions and allow the identification of the root cause of the problem.

Key Players Landscape and Outlook

Various healthcare companies across the globe are actively working on delivering testing solutions that provide rapid and precise results. These companies are also actively working to raise funding to advance endocrine testing technologies. In April 2023, Eli Health raised USD 3.6 million to advance women's health with the help of saliva-based hormone monitoring technology. Hormone fluctuations affect a wide range of conditions, and women experience symptoms through puberty and post-menopause. Despite the accessibility of at-home hormone urine tests, the only options available outside of fertility are not appropriate for long-term and high-frequency testing due to high waiting time and costs. Thus, Eli Health is working on providing real-time insights into hormone levels with the help of saliva testing that can be tracked over time, unlike the traditional tests or methods that can only provide an isolated snapshot of hormone levels.

Similarly, in May 2022, a Berlin-based startup raised approximately USD 10.13 million (€9.3 million) in funding to expand their hormone tracking technology. Their biosensor mini lab allows women to discover their progesterone levels regularly by performing a saliva test. Such funding is expected to aid healthcare companies in bridging the gaps in women's health.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Endocrine Testing Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 4.2.1.2. Insulin Test
      • 4.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 4.2.1.4. Prolactin Test
      • 4.2.1.5. Luteinizing Hormone (LH) Test
      • 4.2.1.6. Progesterone Test
      • 4.2.1.7. Others
    • 4.2.2. By Technology
      • 4.2.2.1. Tandem Mass Spectrometry
      • 4.2.2.2. Immunoassay
      • 4.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 4.2.2.4. Sensor Technology
      • 4.2.2.5. Clinical Chemistry
      • 4.2.2.6. Others
    • 4.2.3. By End-user
      • 4.2.3.1. Hospitals
      • 4.2.3.2. Clinical Laboratories
      • 4.2.3.3. Diagnostic Centers
      • 4.2.3.4. Ambulatory Care Centers
      • 4.2.3.5. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Test Type
    • 4.3.2. By Technology
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. North America Endocrine Testing Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Test Type
      • 5.2.1.1. Thyroid Stimulating Hormone (TSH) Test
      • 5.2.1.2. Insulin Test
      • 5.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
      • 5.2.1.4. Prolactin Test
      • 5.2.1.5. Luteinizing Hormone (LH) Test
      • 5.2.1.6. Progesterone Test
      • 5.2.1.7. Other
    • 5.2.2. By Technology
      • 5.2.2.1. Tandem Mass Spectrometry
      • 5.2.2.2. Immunoassay
      • 5.2.2.3. Monoclonal and Polyclonal Antibody Technologies
      • 5.2.2.4. Sensor Technology
      • 5.2.2.5. Clinical Chemistry
      • 5.2.2.6. Others
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Clinical Laboratories
      • 5.2.3.3. Diagnostic Centers
      • 5.2.3.4. Ambulatory Care Centers
      • 5.2.3.5. Others
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Endocrine Testing Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Test Type
          • 5.3.1.2.1.1. Thyroid Stimulating Hormone (TSH) Test
          • 5.3.1.2.1.2. Insulin Test
          • 5.3.1.2.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
          • 5.3.1.2.1.4. Prolactin Test
          • 5.3.1.2.1.5. Luteinizing Hormone (LH) Test
          • 5.3.1.2.1.6. Progesterone Test
          • 5.3.1.2.1.7. Others
        • 5.3.1.2.2. By Technology
          • 5.3.1.2.2.1. Tandem Mass Spectrometry
          • 5.3.1.2.2.2. Immunoassay
          • 5.3.1.2.2.3. Monoclonal and Polyclonal Antibody Technologies
          • 5.3.1.2.2.4. Sensor Technology
          • 5.3.1.2.2.5. Clinical Chemistry
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By End-user
          • 5.3.1.2.3.1. Hospitals
          • 5.3.1.2.3.2. Clinical Laboratories
          • 5.3.1.2.3.3. Diagnostic Centers
          • 5.3.1.2.3.4. Ambulatory Care Centers
          • 5.3.1.2.3.5. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Endocrine Testing Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Endocrine Testing Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Endocrine Testing Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Endocrine Testing Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Abbott Laboratories
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. bioMerieux SA
    • 20.3.3. Siemens Healthineers AG
    • 20.3.4. Thermo Fisher Scientific Inc.
    • 20.3.5. Agilent Technologies, Inc.
    • 20.3.6. F. Hoffmann-La Roche Ltd
    • 20.3.7. AB Sciex Pte. Ltd.
    • 20.3.8. DiaSorin S.p.A.
    • 20.3.9. Quest Diagnostics Incorporated
    • 20.3.10. Danaher Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 3. Global Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 4. Global Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Endocrine Testing Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 8. North America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 9. North America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 13. United States Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 14. United States Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 17. Canada Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 18. Canada Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 21. Mexico Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 22. Mexico Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 25. Europe Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 26. Europe Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 30. Germany Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 31. Germany Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 34. France Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 35. France Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 38. Italy Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 39. Italy Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 42. United Kingdom Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 43. United Kingdom Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 46. Russia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 47. Russia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 50. Netherlands Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 51. Netherlands Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 54. Spain Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 55. Spain Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 58. Turkey Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 59. Turkey Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 62. Poland Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 63. Poland Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 66. South America Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 67. South America Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 71. Brazil Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 72. Brazil Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 75. Argentina Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 76. Argentina Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 79. Asia-Pacific Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 80. Asia-Pacific Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 82. India Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 84. India Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 85. India Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 88. China Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 89. China Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 92. Japan Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 93. Japan Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 96. Australia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 97. Australia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 100. Vietnam Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 101. Vietnam Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 104. South Korea Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 105. South Korea Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 108. Indonesia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 109. Indonesia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 112. Philippines Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 113. Philippines Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 116. Middle East & Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 117. Middle East & Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Endocrine Testing Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 121. Saudi Arabia Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 122. Saudi Arabia Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 125. UAE Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 126. UAE Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Endocrine Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Endocrine Testing Market Share (%), By Test Type, 2017-2031F
  • Figure 129. South Africa Endocrine Testing Market Share (%), By Technology, 2017-2031F
  • Figure 130. South Africa Endocrine Testing Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023